Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.
Saved in:
| Title: | Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies. |
|---|---|
| Authors: | Tao K; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA., Herschhorn A; Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA., Fera D; Department of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA, USA., Lynch RM; Department of Microbiology, Immunology & Tropical Medicine, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA., Julg BD; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA., Korber B; Los Alamos National Laboratory and The New Mexico Consortium, Los Alamos, NM, USA., Shafer RW; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA. rshafer@stanford.edu. |
| Source: | Communications medicine [Commun Med (Lond)] 2026 May 28; Vol. 6 (1). Date of Electronic Publication: 2026 May 28. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
